Procaps Group (NASDAQ:PROC – Get a rating) has been updated by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report released Friday to clients and investors, Zacks.com reports.
According to Zacks, “Procaps Group is a developer of pharmaceutical and nutraceutical solutions, drugs and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high potency clinical solutions. Procaps Group , formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia.”
NASDAQ:PROC shares opened at $8.85 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt ratio of 3.12. Procaps Group has a 1-year low of $5.86 and a 1-year high of $11.98. The company’s 50-day simple moving average is $8.11 and its two-hundred-day simple moving average is $8.80.
A number of large investors have recently changed their PROC holdings. Penserra Capital Management LLC purchased a new stake in shares of Procaps Group during the fourth quarter valued at approximately $30,000. Geode Capital Management LLC purchased a new stake in shares of Procaps Group during the fourth quarter valued at approximately $107,000. Credit Suisse AG purchased a new equity stake in Procaps Group during the fourth quarter valued at around $169,000. Citadel Advisors LLC purchased a new stake in shares of Procaps Group during the third quarter valued at approximately $458,000. Finally, Itau Unibanco Holding SA increased its position in Procaps Group shares by 148.3% during the fourth quarter. Itau Unibanco Holding SA now owns 297,974 shares of the company valued at $2,861,000 after purchasing an additional 177,974 shares in the last quarter. 1.72% of the shares are currently held by institutional investors and hedge funds.
Procaps Group Company Profile (Get a rating)
Procaps Group SA develops, produces and markets pharmaceutical solutions worldwide. The company formulates, manufactures and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology , vision care, central nervous system and respiratory tract.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Groupe Procaps right now?
Before you consider Procaps Group, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Procaps Group didn’t make the list.
Although Procaps Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here